Zacks Research Brokers Boost Earnings Estimates for BAX

Baxter International Inc. (NYSE:BAX) – Equities researchers at Zacks Research lifted their Q2 2027 EPS estimates for Baxter International in a research report issued on Monday, September 28th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $0.51 per share for the quarter, up from their prior forecast of $0.50. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.04 per share.

Other research analysts have also issued research reports about the company. Citigroup raised Baxter International from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $17.00 to $28.00 in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. UBS Group lifted their target price on shares of Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a report on Tuesday, July 28th. TD Cowen increased their price target on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, July 27th. Finally, Stifel Nicolaus raised their price objective on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Baxter International currently has an average rating of “Hold” and a consensus target price of $22.45.

Baxter International Stock Up 2.5%

Shares of NYSE BAX opened at $24.06 on Tuesday. The stock has a market cap of $12.44 billion, a PE ratio of -11.62, a price-to-earnings-growth ratio of 3.55 and a beta of 0.60. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. Baxter International has a 52-week low of $15.73 and a 52-week high of $30.00. The business has a 50-day moving average price of $25.26 and a 200 day moving average price of $21.24.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same quarter last year, the company posted $0.59 earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS.

Baxter International Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s payout ratio is currently -1.93%.

Hedge Funds Weigh In On Baxter International

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp acquired a new stake in shares of Baxter International in the 2nd quarter valued at approximately $26,000. CYBER HORNET ETFs LLC grew its holdings in Baxter International by 52.4% during the second quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 740 shares during the period. Community Bank N.A. purchased a new position in Baxter International in the second quarter worth $46,000. Versant Capital Management Inc lifted its holdings in Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 2,043 shares during the period. Finally, EFG International AG acquired a new stake in Baxter International in the second quarter valued at $67,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Key Baxter International News

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter released its inaugural Connected Hospital Report, highlighting opportunities to use connectivity, automation and data analytics to improve hospital efficiency and patient care. The report supports the company’s digital-health strategy and could strengthen its long-term growth narrative. Baxter Releases Inaugural Connected Hospital Report
• Neutral Sentiment: Zacks Research raised its estimate for second-quarter 2027 EPS to $0.51 from $0.50, while maintaining a Hold rating. The isolated increase offers limited support, particularly as other, more recent estimate changes were negative. Zacks Research Issues Optimistic Estimate for BAX Earnings
• Negative Sentiment: Zacks lowered its Q3 2026 EPS estimate to $0.51 from $0.53 and reduced its Q4 estimate to $0.60 from $0.62. It also cut full-year 2026 EPS to $2.04 from $2.06, FY2027 EPS to $1.98 from $2.07, and FY2028 EPS to $2.11 from $2.15. The revisions suggest softer near- and medium-term earnings momentum, although the 2026 estimate remains in line with consensus. Baxter International stock faces a Q3 EPS estimate cut
• Negative Sentiment: Additional Zacks cuts reduced Q3 2027 EPS to $0.50 from $0.53 and Q4 2027 EPS to $0.52 from $0.59. Such reductions may pressure the stock by raising concerns about the pace of earnings recovery. Baxter International consensus target price
• Negative Sentiment: BAX is trading above the reported consensus analyst target of $22.45, limiting apparent upside based on current price targets and increasing valuation sensitivity. Baxter International stock trades above analyst target

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops and markets products used in hospitals, outpatient facilities and other care settings. Its portfolio includes intravenous solutions and administration sets, infusion pumps, parenteral nutrition products, injectable medicines, surgical products and systems for medication preparation and delivery.

The company also provides products and technologies that support anesthesia, critical care, patient monitoring and other hospital workflows.